Submit a manuscript Sign up for article alerts Contact us Support

About Journal of Experimental & Clinical Cancer Research

This page includes information about the aims and scope of Journal of Experimental & Clinical Cancer Research, editorial policies, open access and article-processing charges, the peer review process and other information. For details of how to prepare and submit a manuscript through the online submission system, please see the instructions for authors.

Aims & scope

Journal of Experimental & Clinical Cancer Research is an online peer-reviewed journal that provides a high-quality forum for all aspects of basic, clinical and translational work in oncology. Topics covered include:

  • Hematology
  • Molecular and cellular pathology
  • Oncogenomics proteomics and metabolomics
  • Microenviromental
  • Prevention and epidemiology
  • Therapeutics and targets
  • Tumor and stem cell biology
  • Tumor immunology and virology

The journal publishes scientific studies on the immunological, epidemiological, pathological, biological and clinical aspects of oncology. Topics considered range from molecular genetics via infectious agents to surgery and therapeutic approaches and outcomes. Systematic reviews of clinical and basic research, as well as clinical practice guidelines, are especially welcome.

JECCR has been publishing since 1982. Prior to 2008, JECCR was published in print. For enquiries about previous content, please contact editorial@jeccr.com.

Open access

All articles published by Journal of Experimental & Clinical Cancer Research are made freely and permanently accessible online immediately upon publication, without subscription charges or registration barriers. Further information about open access can be found here.

Authors of articles published in Journal of Experimental & Clinical Cancer Research are the copyright holders of their articles and have granted to any third party, in advance and in perpetuity, the right to use, reproduce or disseminate the article, according to the BioMed Central copyright and license agreement.

For authors who are US government employees or are prevented from being copyright holders for similar reasons, BioMed Central can accommodate non-standard copyright lines. Please contact us if further information is needed.

Article-processing charges

Open access publishing is not without costs. Journal of Experimental & Clinical Cancer Research therefore levies an article-processing charge of £1240/$2110/€1570 for each article accepted for publication. If the submitting author's institution is a Member, the cost of the article-processing charge is covered by the membership, and no further charge is payable. In the case of authors whose institutions are Supporter Members, however, a discounted article-processing charge is payable by the author. We routinely waive charges for authors from low-income countries. For other countries, article-processing charge waivers or discounts are granted on a case-by-case basis to authors with insufficient funds. Authors can request a waiver or discount during the submission process. For further details, see our article-processing charge page.

Indexing services

All articles published in Journal of Experimental & Clinical Cancer Research are included in PubMed, the most widely used biomedical bibliographic database service, which is run by the US National Library of Medicine. Other bibliographic databases that index articles published in Journal of Experimental & Clinical Cancer Research include:

  • CAS
  • Citebase
  • Current contents
  • DOAJ
  • Embase
  • Google Scholar
  • MEDLINE
  • OAIster
  • PubMed
  • PubMed Central
  • Science Citation Index Expanded
  • SCImago
  • Scopus
  • SOCOLAR
  • Zetoc

The full text of all research articles is deposited in PubMed Central, the US National Library of Medicine's full-text repository of life science literature, and other digital archives including e-Depot (The Netherlands).

The full text of all research articles published by BioMed Central is also available on SpringerLink.

Journal of Experimental & Clinical Cancer Research is tracked by Thomson Reuters (ISI) and has an Impact Factor of 3.27.

Publication and peer review process

Criteria for publication

Journal of Experimental & Clinical Cancer Research considers the following types of article:

Research: reports of data from original research.

Reviews: comprehensive, authoritative, descriptions of any subject within the scope of the journal. These articles are usually written by opinion leaders that have been invited by the Editorial Board.

Case reports: reports of clinical cases that can be educational, describe a diagnostic or therapeutic dilemma, suggest an association, or present an important adverse reaction. All case report articles should indicate that informed consent to publish the information was granted from the patients or their guardians.

Peer-review policies

Journal of Experimental & Clinical Cancer Research has a ‘closed’ peer review policy. After an initial screening for general suitability, new submissions will be sent to at least two recognised experts in the field for peer review. In cases of conflicting reports a third reviewer will be consulted, but final decisions will rest with the Editor-in-Chief. The journal aims to provide authors with a first decision (accepted/rejected/revisions needed) within six weeks.

Where authors are unhappy about decisions, the Editor-in-Chief and the Regional Editors will discuss the situation. Should there be at least one Editor in favor of reconsideration, the authors will be offered another round of peer review.

Edited by Mauro Castelli, Journal of Experimental & Clinical Cancer Research is supported by an expert Editorial Board.

Authors will be able to check the progress of their manuscript through the submission system at any time by logging into My Journal of Experimental & Clinical Cancer Research, a personalized section of the site.

Reprints

High-quality, bound reprints can be purchased for all articles published. Please see our reprints website for further information about ordering reprints.

Supplements

Journal of Experimental & Clinical Cancer Research will consider supplements based on proceedings (full articles or meeting abstracts), reviews or research. All articles submitted for publication in supplements are subject to peer review. Published supplements are fully searchable and freely accessible online and can also be produced in print. All full length articles (proceedings, reviews or research articles) are indexed by PubMed. PubMed displays the title of the supplement only in the case of meeting abstract collections. For further information, please contact us.

Editorial policies

All manuscripts submitted to Journal of Experimental & Clinical Cancer Research should adhere to BioMed Central's editorial policies.

Citing articles in Journal of Experimental & Clinical Cancer Research

Articles in Journal of Experimental & Clinical Cancer Research should be cited in the same way as articles in a traditional journal. Because articles are not printed, they do not have page numbers; instead, they are given a unique article number.

Article citations follow this format:

Authors: Title. J Exp Clin Cancer Res [year], [volume number]:[article number].

e.g. Roberts LD, Hassall DG, Winegar DA, Haselden JN, Nicholls AW, Griffin JL: Increased hepatic oxidative metabolism distinguishes the action of Peroxisome Proliferator-Activated Receptor delta from Peroxisome Proliferator-Activated Receptor gamma in the Ob/Ob mouse. J Exp Clin Cancer Res 2009, 1:115.

refers to article 115 from Volume 1 of the journal.

Why publish your article in Journal of Experimental & Clinical Cancer Research?

High visibility

Journal of Experimental & Clinical Cancer Research's open access policy allows maximum visibility of articles published in the journal as they are available to a wide, global audience. Articles that have been especially highly accessed are highlighted with a 'Highly accessed' graphic, which appears on the journal's contents pages and search results.

Speed of publication

Journal of Experimental & Clinical Cancer Research offers a fast publication schedule whilst maintaining rigorous peer review; all articles must be submitted online, and peer review is managed fully electronically (articles are distributed in PDF form, which is automatically generated from the submitted files). Articles will be published with their final citation after acceptance, in both fully browsable web form, and as a formatted PDF; the article will then be available through Journal of Experimental & Clinical Cancer Research, BioMed Central and PubMed Central and will also be included in PubMed.

Flexibility

Online publication in Journal of Experimental & Clinical Cancer Research gives authors the opportunity to publish large datasets, large numbers of color illustrations and moving pictures, to display data in a form that can be read directly by other software packages so as to allow readers to manipulate the data for themselves, and to create all relevant links (for example, to PubMed, to sequence and other databases, and to other articles).

Promotion and press coverage

Articles published in Journal of Experimental & Clinical Cancer Research are included in article alerts and regular email updates. Some may be included in abstract books mailed to academics and are highlighted on Journal of Experimental & Clinical Cancer Research's pages and on the BioMed Central homepage.

In addition, articles published in Journal of Experimental & Clinical Cancer Research may be promoted by press releases to the general or scientific press. These activities increase the exposure and number of accesses for articles published in Journal of Experimental & Clinical Cancer Research. A list of articles recently press-released by journals published by BioMed Central is available here.

Authors of articles published in Journal of Experimental & Clinical Cancer Research retain the copyright of their articles and are free to reproduce and disseminate their work (for further details, see the BioMed Central copyright policy and license agreement).

For further information about the advantages of publishing in a journal from BioMed Central, please click here.